Method for producing composition containing fucoxanthin
US-9199952-B2 · Dec 1, 2015 · US
Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
US12083091B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12083091-B2 |
| Application number | US-202017036860-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2020 |
| Priority date | Apr 11, 2016 |
| Publication date | Sep 10, 2024 |
| Grant date | Sep 10, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of a disease of the motor units, wherein the disease is Amyotrophic Lateral Sclerosis (ALS), and wherein the method comprises administering to a patient in need thereof a pharmaceutical composition consisting of ambroxol and/or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier. 2. The method according to claim 1 wherein the pharmaceutical composition is administered to the patient at a dose of 0.01 to 500 mg/kg of body weight/day. 3. The method according to claim 1 wherein the pharmaceutical composition is administered to the patient at a dose of 0.1 to 250 mg/kg of body weight/day.
Assignees
Inventors
Classifications
Drugs for disorders of the muscular or neuromuscular system · CPC title
not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title
Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title
only substituted in position 1, e.g. propipocaine, diperodon · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12083091B2 cover?
- Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.
- Who is the assignee on this patent?
- Spedding Res Solutions, Univ Strasbourg, Inserm—Institut National De La Sante Et De La Rech Medicale
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).